CLIA-Waived Test

A CLIA-waived test is a laboratory test that the FDA has determined is simple enough and accurate enough that it can be performed under a Certificate of Waiver — the least burdensome of the five certificate types under the Clinical Laboratory Improvement Amendments (CLIA), 42 CFR Part 493. A facility holding only a Certificate of Waiver can legally perform waived tests without the personnel-qualification requirements, proficiency-testing enrollment, and routine on-site inspections that apply to moderate- and high-complexity testing; it still has to follow the manufacturer’s instructions exactly and enroll in the certificate program itself, but it is not subject to CLIA’s full quality-system requirements.

What makes a test CLIA-waived

Test complexity under CLIA is assigned by the FDA, not by CMS (which issues the certificates) or CDC (which provides scientific/technical support through CLIAC). A test earns waived status when the FDA determines, under the criteria at 42 CFR 493.15, that it:

• employs methodology “so simple and accurate as to render the likelihood of erroneous results negligible,” and
• poses no reasonable risk of harm to the patient if performed incorrectly.

In practice this almost always means a single-use or cartridge-based test, minimal or no calibration by the operator, a built-in or visual internal control, and a qualitative or simple quantitative result — not an assay requiring judgment calls, multi-step sample preparation, or operator-dependent technique. The FDA publishes and continuously updates the authoritative list of currently waived tests and systems; because manufacturers add new waived devices on an ongoing basis, that FDA database (not a fixed printed list) is the only source that should be treated as current for a specific instrument or kit.

Examples of CLIA-waived tests

Waived tests span most point-of-care settings — physician offices, urgent care, pharmacies, school and workplace health clinics, and correctional and public-health settings. Common examples include:

• Blood glucose meters used for point-of-care glucose monitoring.
• Rapid antigen tests for Group A Streptococcus, influenza A/B, and COVID-19.
• Urine dipstick/reagent-strip urinalysis read visually or with a small waived analyzer.
• Visual or cassette-based urine hCG pregnancy tests.
• Fecal occult blood tests.
• Point-of-care INR/PT monitors used for warfarin management.
• Point-of-care hemoglobin A1c analyzers cleared for CLIA-waived use.
• Single-use urine or oral-fluid drug-of-abuse screening cups and cassettes — see below.

This is illustrative, not exhaustive — there is no fixed universe of “the” waived tests, since the list only ever reflects whatever devices currently hold FDA CLIA-waived status.

CLIA-waived drug tests

“CLIA waived drug test” is one of the most frequent real-world searches behind this term, because point-of-care drug screening sits squarely in the waived category for a specific reason: most single-panel and multi-panel urine or oral-fluid drug-of-abuse test cups and cassettes are qualitative, visually-read immunoassays — a colored line either appears or doesn’t at a fixed cutoff concentration — which is exactly the “simple and accurate, negligible risk of erroneous result” profile the waiver criteria describe. That is why occupational-health clinics, pain-management practices, drug courts, treatment programs, and employer drug-testing programs can run these screens under a Certificate of Waiver rather than a full clinical laboratory license.

The waiver only covers the screening step, though. A presumptive positive (or any result that will be used for a legally or medically consequential decision, such as employment action or a for-cause result) is standard practice to send for confirmatory testing by GC-MS or LC-MS/MS at a certified reference laboratory. Quantitative confirmatory testing is high-complexity under CLIA and cannot be performed under a Certificate of Waiver — see the counter-example below.

What is NOT CLIA-waived (a counter-example)

A test does not become waived just because it is quick or run on a small benchtop device. Two useful contrasts:

• Confirmatory drug testing (GC-MS/LC-MS/MS). Quantitative, instrument-based confirmation of a presumptive-positive screen is high-complexity testing. It requires a Certificate of Compliance or Certificate of Accreditation, qualified laboratory personnel, and participation in proficiency testing — it cannot be performed under a Certificate of Waiver, even though the initial screening cup that flagged the sample was waived.
• Provider-performed microscopy (PPM) procedures — e.g., wet mounts, KOH preps, urine sediment exam — are their own separate, moderate-complexity category. They require a distinct Certificate for PPM Procedures, not a Certificate of Waiver, even though a physician or midlevel provider performs them at the point of care.

A lab holding only a Certificate of Waiver that runs a non-waived test is operating outside its certificate — a real compliance exposure, not a technicality, and one CMS surveys for.

Frequently asked questions

What does CLIA waived mean?

It means the FDA has determined a specific test system is simple and accurate enough to be performed under the least restrictive CLIA certificate (the Certificate of Waiver), without the personnel, proficiency-testing, and inspection requirements that apply to moderate- and high-complexity testing. “Waived” describes the test’s complexity category, not the facility — a single lab can hold waived tests alongside moderate- or high-complexity ones if it holds the appropriate broader certificate.

Who decides which tests are CLIA waived?

The FDA assigns test complexity categories, including waived status, as part of clearing or approving a test system (or through the CLIA Waiver by Application pathway for a test already cleared as moderate complexity). CMS administers the certificate program built on top of that categorization; CDC/CLIAC provide scientific and technical guidance to the program but do not themselves categorize individual tests.

Does a CLIA Certificate of Waiver mean no oversight at all?

No. A waived-testing facility still must enroll in CLIA, follow manufacturer instructions exactly, and is subject to random CMS validation surveys (a smaller share of waived-only labs are inspected than moderate/high-complexity labs, but the exposure is real, not zero). It is exempt from the routine biennial survey cycle and detailed personnel/QC/proficiency-testing subparts that apply to non-waived testing.

Is a rapid at-home-style test automatically CLIA waived if a clinic uses it?

Only if that specific test system holds current FDA CLIA-waived status for use in a professional setting under a Certificate of Waiver — being sold for home use is a strong signal but not the legal basis. The FDA’s current waived-tests database is the source to check for a specific device, not the packaging or a vendor’s marketing claim.

Related reading

For the full picture of CLIA certificate types, complexity categories, and whether a given laboratory needs a certificate at all (including the research-laboratory exemption under 42 CFR 493.3), see CASRAI’s guide to CLIA certification.